Fairvalue-Calculator Fairvalue-Calculator
EN DE

enGene Therapeutics Inc (ENGN) Fair Value & Analysis

Healthcare · US · Market cap $115M

Price$1.75
Fair Value$2.20
Upside+25.7%
Quality95/100
Evidence: Low Range $1.45 – $2.75

Fair value as of: Jun 25, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

enGene Therapeutics Inc (ENGN) currently trades at $1.75, while our model-based Fair Value estimate is $2.20 — implying the stock looks roughly 25.7% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -84% Regeneron Pharmaceuticals, Inc (REGN) +109% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +9% Alnylam Pharmaceuticals, Inc (ALNY) -64%

Frequently asked questions

Is enGene Therapeutics Inc (ENGN) undervalued?
As of Jun 25, 2026, our model estimates a fair value of $2.20 versus a price of $1.75 — about +26% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ENGN?
Our 21-model fair value for enGene Therapeutics Inc is $2.20 (as of Jun 25, 2026), built from audited fundamentals. The current price is $1.75.
What is the quality score of ENGN?
enGene Therapeutics Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.